New Report Says High Priced Vaccines Will Spur Four-fold Growth In Paediatric And Adolescent Vaccines Market By 2016

The report draws attention to how various high price vaccines have received different reception in the market. For instance, Wyeth’s Prevnar and Merck & Co’s Gardasil have experienced a rapid uptake driven by obvious medical need and public attention. End Quote

(1888PressRelease) December 20, 2007 - Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that after years of stagnation in the childhood and adolescent vaccines sector, the launch of new, high price vaccines against pneumococcal infections and human papillomavirus has propelled rapid growth in the market.

“Pipeline and Commercial Insight: Pediatric and Adolescent Vaccines” finds that the market will nearly quadruple in size to $16 billion by 2016.

The report draws attention to how various high price vaccines have received different reception in the market. For instance, Wyeth’s Prevnar and Merck & Co’s Gardasil have experienced a rapid uptake driven by obvious medical need and public attention. On the other hand, other vaccines such as Merck & Co’s RotaTeq have failed to make it into routine vaccination schedules due to costs.

The publication predicts that total annual sales will remain limited to approximately $1 billion for rotavirus vaccines across the seven major markets by 2016. The US will account for the majority of sales, as it has recommended rotavirus vaccination for all infants.

Authors say that childhood and adolescent vaccination across the western world had long centered around established and cheap vaccines to prevent diseases such as diphtheria, tetanus, pertussis, mumps, measles and rubella.

They point out that beginning with the launch of Wyeth’s pneumococcal vaccine Prevnar in 2000, the sector has experienced a rapid introduction of novel, high-price vaccines for additional diseases, including the human papillomavirus vaccines – Gardasil (Merck & Co) and Cervarix (GlaxoSmithKline), as well as the rotavirus vaccines – RotaTeq (Merck & Co) and Rotarix (GlaxoSmithKline).

Analysts say this development has sparked new interest from big pharma in the paediatric and adolescent vaccines market. The study provides discussion of the pediatric and adolescent vaccines market including epidemiology, market drivers and strategic analysis of key companies. Assessment of marketed and pipeline products. Patient-based forecast of market size and coverage rates to 2016.

“Pipeline and Commercial Insight: Pediatric and Adolescent Vaccines” is available from Report Buyer.

Report Buyer product ID: DAT06315

http://www.reportbuyer.com/pharma_healthcare/research_r_d_/pipeline/pipeline_commercial_insight.html

About Report Buyer
Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare. The website now carries over 40,000 business information products, including market reports, studies and books. Report Buyer is the intelligent way to buy market research making it an essential resource for executives and information buyers worldwide. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.

http://digbig.com/4rgca

###

Visit Report Buyer Website

space